EMA Authorised: Enflonsia (clesrovimab) — Merck Sharp Dohme Limited

View source ↗

Summary

The European Medicines Agency authorised Enflonsia (clesrovimab) from Merck Sharp & Dohme Limited for use against Respiratory Syncytial Virus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• ENFLONSIA (CLESROVIMAB)

Snippet

Status: Authorised. Therapeutic area: Respiratory Syncytial Virus Vaccines. MAH: Merck Sharp Dohme Limited. Decision date: 15/04/2026